

## Dicot in preparation for clinical phase 2a trial

**Press release: Uppsala, Sweden, April 12, 2024. The pharmaceutical company Dicot, which recently announced that a reporting from the last part of the phase 1 study will be published at the end of April, is in parallel preparing for a clinical phase 2a trial with its potency drug candidate. Today, the company can announce that a partner has been contracted to conduct the trial and that the study drug has been produced by Thermo Fisher Scientific, the contracted manufacturer.**

Dicot will soon report the results from the last part in the clinical phase 1 study. In parallel, preparatory activities are underway to be able to start a clinical phase 2a study in the second half of 2024. An important part of the preparations is the procurement of a Clinical Research Organization to conduct the study. Dicot has now chosen Clinical Trial Consultants AB, who also leads the clinical work in the current phase 1 study. CTC is a reputable contract research organization with over 400 completed studies for both smaller and larger international pharmaceutical companies.

Furthermore, the American contract manufacturer Thermo Fisher Scientific has now completed production of the study drug according to Good Manufacturing Practice to be used in the study.

"It's great that these important pieces of the puzzle are in place. It also means that we have the pleasure of continuing to collaborate with these two highly professional companies," says Elin Trampe, Dicot's CEO.

### **For further information, please contact:**

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: [elin.trampe@dicot.se](mailto:elin.trampe@dicot.se)

### **About Dicot AB**

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 5,300 shareholders. For more information, please visit [www.dicot.se](http://www.dicot.se).

---